ZEISS and Boehringer Ingelheim Partner on AI-Powered Platform to Transform Ophthalmic Research and Personalized Eye Care
核心洞察
ZEISS (搜索) unveils its Research Data Platform (RDP), an AI (搜索)-driven cloud-based solution that integrates clinical and research data to accelerate discoveries in ophthalmology through more efficient research workflows.
The strategic collaboration between ZEISS (搜索) and Boehringer Ingelheim aims to develop earlier detection and prediction capabilities for chronic retinal diseases (搜索), potentially transforming treatment approaches through personalized care.
Industry experts will present on AI (搜索)'s future role in ophthalmology and addressing unmet needs at the ARVO 2025 conference, where ZEISS (搜索) will showcase its latest innovations from May 4-8 in Salt Lake City.
ZEISS (搜索) has unveiled its new AI (搜索)-powered Research Data Platform (ZEISS RDP) at the Association for Research in Vision and Ophthalmology (ARVO) conference, while highlighting its ongoing collaboration with Boehringer Ingelheim to advance personalized eye care for patients with chronic retinal diseases (搜索).
The cloud-based ZEISS (搜索) RDP represents a significant advancement in ophthalmic research technology, designed to transform how clinicians and researchers collect, integrate, and analyze data. Following successful pilot testing, the platform is scheduled for launch in select countries throughout 2025.
"The future of healthcare is in the data," said Euan S. Thomson, Ph.D., Head of the Digital Business Unit for ZEISS (搜索) Medical Technology. "At ZEISS, we are delivering digital innovation to help shape the future of ophthalmology, investing in research methods that empower clinicians and researchers in balancing their clinical care and research requirements."
Transforming Research Through AI Technology
The ZEISS (搜索) RDP offers three key capabilities that promise to revolutionize ophthalmic research:
First, it accelerates research breakthroughs by enabling clinicians and researchers to convert research hypotheses into quantifiable biomarkers using AI (搜索)-powered tools. Users can train their own algorithms and leverage AI for complex data analysis, significantly improving efficiency.
Second, it unifies research data by aggregating diverse datasets from multiple sources, facilitating comprehensive analysis of both medical and surgical imaging data. The platform maintains security through user-based access controls, allowing research teams to retain full ownership of their data.
Third, it streamlines research workflows by integrating research and clinical processes. Automated data collection from systems like ZEISS (搜索) FORUM reduces manual transfers and errors, enhancing overall workflow efficiency.
Strategic Collaboration with Boehringer Ingelheim
The partnership between ZEISS (搜索) Medical Technology and Boehringer Ingelheim focuses on leveraging data-driven AI (搜索) to develop earlier detection and prediction capabilities for chronic retinal diseases (搜索). This collaboration aims to preserve vision through new treatment pathways and more personalized care approaches.
Heiko G. Niessen, Ph.D., Global Head of Translational Medicine, Eye Health, at Boehringer Ingelheim, emphasized the importance of early intervention: "At Boehringer Ingelheim, we're working toward a future in which earlier detection and intervention result in long-term, real-world outcomes that prevent vision loss due to chronic retinal diseases (搜索). Our collaboration with ZEISS (搜索) Medical Technology exemplifies our strategy to work with like-minded partners who share our goal of preserving and protecting eyesight and people's way of life."
ZEISS (搜索) contributes its Medical Ecosystem capabilities—connecting devices and data to enable next-generation analytics and AI (搜索) technologies—while Boehringer Ingelheim brings expertise in discovering and developing breakthrough therapies for underserved medical conditions.
Expert Perspectives at ARVO 2025
The collaboration will be highlighted during expert talks on May 7 at the ARVO conference, featuring presentations from leading ophthalmology researchers:
-
Pearse Keane, Professor of Artificial Intelligence at UCL Institute of Ophthalmology and consultant ophthalmologist at Moorfields Eye Hospital, will present "The Practice of 2030: How Will AI (搜索) Support You?"
-
Sobha Sivaprasad, Professor of Retinal Clinical Research at UCL Institute of Ophthalmology and consultant ophthalmologist at Moorfields Eye Hospital, will discuss "How to Tackle Unmet Needs and Treat Diseases Early in the Future?"
Thomson highlighted the strategic importance of the partnership: "Our partnership with Boehringer Ingelheim personifies our strategic focus to drive innovation through collaboration. We're harnessing data ecosystems in new ways, enabling partners like Boehringer Ingelheim to make breakthrough discoveries to combat vision problems and improve people's lives."
Addressing Unmet Needs in Ophthalmology
Chronic retinal diseases (搜索) represent a significant burden on patients and healthcare systems worldwide. Conditions like diabetic retinopathy (搜索) and age-related macular degeneration (搜索) remain leading causes of vision loss globally, with current treatments often initiated after irreversible damage has occurred.
The collaboration between ZEISS (搜索) and Boehringer Ingelheim aims to address these challenges by developing tools for earlier detection and more personalized treatment approaches. By integrating clinical and research data through the ZEISS RDP, researchers hope to identify biomarkers and patterns that could predict disease progression before symptoms appear.
Future Implications for Clinical Practice
The technologies being developed through this partnership could significantly impact clinical ophthalmology practice. AI (搜索)-powered analysis of retinal imaging could enable more precise diagnosis and treatment planning, while integration of diverse data sources might reveal previously unrecognized patterns in disease progression.
For patients with chronic retinal diseases (搜索), these advancements could translate to preservation of vision through earlier interventions and more tailored treatment approaches. The ability to predict disease progression could also allow for preventive measures before significant vision loss occurs.
ZEISS (搜索) will showcase its latest technology innovations and research findings at the ARVO conference from May 4-8, 2025, in Salt Lake City, Utah, at booth #1729, while Boehringer Ingelheim will present at booth #1629.